login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
New Engineered Drug Shows Promise in Treating Lymphocytic Leukaemia
The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.
The research has established that an engineered drug candidate is promising in treating lymphocytic leukemia in both test tube and early animal tests.
The agent represents a new class of agents called small modular immunopharmaceuticals. This agent, which is called CD37-SMIP, targets a protein called CD37 on the surface of these leukemia cells.
The study shows that the agent can successfully attach to the protein on the leukemia cells and destroy them. It works both by activating the cells' self-destruction and by causing a particular class of immune cells to attack them.
In an animal model, the agent worked uniformly over and above the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.
"Our findings have significant implications for the treatment of CLL and related malignancies," says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.
Overall, Byrd says, "the findings point out that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein."
|
|
|
More News on: Drug Toxicity, Signature Drug Toxicity
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
- News Quick Links
| News Categories: |
| » | Schizophrenia Drug Differentiates Cancer Stem Cells into Less Threatening Cells |
| » | Docs Who Seldom Meet Drug Reps Continue to Prescribe Drugs With FDA “Black Box” Warnings |
| » | Revision in Quality Standards for Heparin |
| » | Acne Drug Users At High Risk of Developing Eye Infections |
| » | Patients Who Take Antidepressants When in ICU More Likely to Die |
| More Drug News | |
|
